1. Stock MJ . Sibutramine: a review of the pharmacology of a novel anti-obesity agent Int J Obes Relat Metab Disord 1997 21 (Suppl 1): S25–S29.
2. Heal DJ, Cheetham SC . The pharmacology of sibutramine, the first serotonin and noradrenaline reuptake inhibitor to be developed for the treatment of obesity Lettre Pharmac 1997 11 (Suppl 10): 3–8.
3. Heal DJ, Aspley S, Prow MR, Jackson HC, Martin KF, Cheetham SC . Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine Int J Obes Relat Metab Disord 1998 22 (Suppl 1): S18–S28.
4. Cheetham SC, Viggers JA, Slater NA, Heal DJ, Buckett WR . [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]-5-HT uptake: effect of administration of various antidepressant treatments Neuropharmacology 1993 32: 737–743.
5. Cheetham SC, Viggers JA, Butler SA, Prow MR, Heal DJ . [3H]Nisoxetine—a radioligand for noradrenaline reuptake sites: correlation with inhibition of [3H]noradrenaline uptake and effect of DSP-4 lesioning and antidepressant treatments Neuropharmacology 1996 35: 63–70.